EUVIMEDEUVIMED entdecken
Crossref

Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors

Michelle Oti-Bronya, Huan Gong iD, Anirban Das iD, Elise M Brown, Henry M Zutter, J Daniel Griffin, Cory Berkland iD, Jai S Rudra iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5596-5608

DOI: 10.1021/acs.molpharmaceut.6c00718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 29.09.2026. Verfasst von Michelle Oti-Bronya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, Saint Louis, Missouri63130, United States. Hauptthemen laut MEDLINE: Glatiramer Acetate, Peptides, Colonic Neoplasms. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases, Washington University in St. Louis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glatiramer acetate (GA) is a heterogeneous mixture of peptides that we have previously explored as an intratumoral immunomodulator. However, its chemical complexity complicates the mechanistic interpretation and rational design. In this study, we evaluated a set of sequence-defined “glatiramoid” peptides engineered to preserve the amino acid composition while varying the primary sequence. Biophysical characterization by circular dichroism, fluorescence spectroscopy, and transmission electron microscopy revealed sequence-dependent differences in supramolecular organization without pronounced changes in the secondary structure. Treatment of murine bone marrow-derived dendritic cells with these peptides produced distinct innate cytokine and chemokine secretion profiles, suggesting that sequence order influences immune signaling outcomes in vitro. In the CT26 mouse model of colon carcinoma, intratumoral administration of selected glatiramoid peptides in combination with anti-PD-1 therapy produced tumor growth responses that were not statistically distinguishable from those of commercial GA formulations. Systemic cytokine levels measured at study termination were generally lower for the sequence-defined peptide relative to GA. Together, these findings indicate that sequence-defined glatiramoid peptides reproduce selected GA-like biophysical and immunomodulatory properties. Further studies are required to establish their mechanisms of action, intratumoral behavior, and therapeutic contribution to checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glatiramer AcetatePeptidesColonic NeoplasmsAnimalsMiceDendritic CellsCytokinesFemaleCell Line, TumorMice, Inbred BALB CHumans

Stichwörter der Autor:innen

checkpoint blockadeglatiramer acetateintratumoral immunotherapysequence-defined peptidessupramolecular peptide assembly

Substanzen

Glatiramer AcetatePeptidesCytokines

Autor:innen und Institutionen

  • Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, Saint Louis, Missouri63130, United States.
  • Department of Chemistry, Washington University in St. Louis, Saint Louis, Missouri63130, United States.
  • Kinimmune Inc., Saint Louis, Missouri63141, United States.

ORCID-Profile: Huan Gong, Anirban Das, Cory Berkland, Jai S Rudra

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Washington University in St. Louis

Zitieren

APA

Oti-Bronya, M., Gong, H., Das, A., Brown, E. M., Zutter, H. M., Griffin, J. D., Berkland, C., & Rudra, J. S. (2026). Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors. Molecular Pharmaceutics, 23(11), 5596-5608. https://doi.org/10.1021/acs.molpharmaceut.6c00718

Vancouver

Oti-Bronya M, Gong H, Das A, Brown EM, Zutter HM, Griffin JD, et al. Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors. Molecular Pharmaceutics. 2026;23(11):5596-5608. doi:10.1021/acs.molpharmaceut.6c00718

BibTeX
@article{OtiBronya2026,
  author = {Oti-Bronya, Michelle and Gong, Huan and Das, Anirban and Brown, Elise M and Zutter, Henry M and Griffin, J Daniel and Berkland, Cory and Rudra, Jai S},
  title = {Engineered Glatiramoid Peptides Emulate Glatiramer Acetate Activity in Solid Tumors},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5596--5608},
  doi = {10.1021/acs.molpharmaceut.6c00718}
}
Kostenlos starten →